AI assistant
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2023
Nov 16, 2023
30849_dirs_2023-11-16_68ac1af9-8f92-4c41-9e73-8c2e2c429918.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2023-11-14
Reporting Person: Smith Hunter C (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-11-14 | Common Stock | M | 12000 | $6.88 | Acquired | 73406 | Direct |
| 2023-11-14 | Common Stock | S | 12000 | $30.3811 | Disposed | 61406 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-11-14 | Stock Option (Right to Buy) | $6.88 | M | 12000 | Disposed | 2027-08-08 | Common Stock (12000) | Direct |
Footnotes
F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2022.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $30.00 to $30.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The stock options is fully vested.